Emerging evidence suggests that semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), may offer a more comprehensive therapeutic approach for male infertility associated with diabetes and obesity. The gene discussed is GLP1R; the disease is Obesity.